AU2017397778B2 - Anti-coagulation factor XI antibody - Google Patents

Anti-coagulation factor XI antibody Download PDF

Info

Publication number
AU2017397778B2
AU2017397778B2 AU2017397778A AU2017397778A AU2017397778B2 AU 2017397778 B2 AU2017397778 B2 AU 2017397778B2 AU 2017397778 A AU2017397778 A AU 2017397778A AU 2017397778 A AU2017397778 A AU 2017397778A AU 2017397778 B2 AU2017397778 B2 AU 2017397778B2
Authority
AU
Australia
Prior art keywords
cdr
antibody
seq
antibodies
prt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017397778A
Other languages
English (en)
Other versions
AU2017397778A1 (en
Inventor
Xiaowu Liu
Wenyi Wang
Quan Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Benemae Pharmaceutical Corp
Original Assignee
Shanghai Benemae Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Benemae Pharmaceutical Corp filed Critical Shanghai Benemae Pharmaceutical Corp
Publication of AU2017397778A1 publication Critical patent/AU2017397778A1/en
Application granted granted Critical
Publication of AU2017397778B2 publication Critical patent/AU2017397778B2/en
Priority to AU2025203303A priority Critical patent/AU2025203303A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017397778A 2017-02-10 2017-12-29 Anti-coagulation factor XI antibody Active AU2017397778B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025203303A AU2025203303A1 (en) 2017-02-10 2025-05-08 Anti-coagulation factor XI antibody

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710073984.XA CN108409863B (zh) 2017-02-10 2017-02-10 抗凝血因子xi抗体
CN201710073984.X 2017-02-10
PCT/CN2017/119856 WO2018145533A1 (zh) 2017-02-10 2017-12-29 抗凝血因子xi抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025203303A Division AU2025203303A1 (en) 2017-02-10 2025-05-08 Anti-coagulation factor XI antibody

Publications (2)

Publication Number Publication Date
AU2017397778A1 AU2017397778A1 (en) 2019-10-03
AU2017397778B2 true AU2017397778B2 (en) 2025-03-06

Family

ID=63107934

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017397778A Active AU2017397778B2 (en) 2017-02-10 2017-12-29 Anti-coagulation factor XI antibody
AU2025203303A Pending AU2025203303A1 (en) 2017-02-10 2025-05-08 Anti-coagulation factor XI antibody

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025203303A Pending AU2025203303A1 (en) 2017-02-10 2025-05-08 Anti-coagulation factor XI antibody

Country Status (9)

Country Link
EP (1) EP3581587B1 (enExample)
JP (1) JP7271430B2 (enExample)
KR (1) KR102690437B1 (enExample)
CN (1) CN108409863B (enExample)
AU (2) AU2017397778B2 (enExample)
BR (1) BR112019016300A2 (enExample)
CA (1) CA3054322A1 (enExample)
MX (1) MX2019009500A (enExample)
WO (1) WO2018145533A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020029179A1 (en) * 2018-08-09 2020-02-13 Shanghai Benemae Pharmaceutical Corporation Anti-factor xi antibodies
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
CN110878123B (zh) * 2018-09-05 2022-08-23 华瑞同康生物技术（深圳）有限公司 一种抗tk1原核重组单链抗体及制备方法
EP3914624A4 (en) * 2019-01-21 2022-10-19 Aronora, Inc. NOVEL HUMANIZED ANTIBODIES AGAINST FACTOR XI HAVING ANTI-THROMBOTIC AND ANTI-INFLAMMATORY EFFECTS AND ASSOCIATED USES
CN113474374B (zh) * 2019-04-16 2025-05-02 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
CN110423278B (zh) 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
CN110498839A (zh) * 2019-09-19 2019-11-26 河南省农业科学院 氟罗沙星单链抗体关键多肽序列及应用
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
TWI882142B (zh) * 2020-07-02 2025-05-01 大陸商北京拓界生物醫藥科技有限公司 抗FXI/FXIa抗體、其抗原結合片段及醫藥用途
CN116589588B (zh) * 2023-04-14 2023-12-22 北京基科晟斯医药科技有限公司 结合凝血因子x的抗体
WO2025130748A1 (zh) * 2023-12-22 2025-06-26 四川科伦博泰生物医药股份有限公司 一种抗凝血因子XI/XIa抗体制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067660A2 (en) * 2007-11-21 2009-05-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2981754B2 (ja) * 1990-02-02 1999-11-22 第一化学薬品株式会社 血液凝固第▲ｘ▼▲ｉｉｉ▼因子に対するモノクロナール抗体
KR100925348B1 (ko) * 2001-06-12 2009-11-09 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 인간형 항-혈액 응고 인자 ⅷ 항체
DE10205520A1 (de) * 2002-02-08 2003-08-14 Aventis Behring Gmbh Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
AU2009335643B2 (en) * 2008-12-18 2014-05-29 Oregon Health & Science University Anti-fXI antibodies and methods of use
SI2847228T1 (sl) * 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3325010B1 (en) * 2015-07-23 2023-06-21 The Regents of The University of California Antibodies to coagulation factor xia and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067660A2 (en) * 2007-11-21 2009-05-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATAFONOV, A. ET AL.: "Evidence for Factor IX-Independent Roles for Factor XIa in Blood Coagulation", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 11, 31 December 2013 (2013-12-31), pages 2118 - 2127, XP055293618 *

Also Published As

Publication number Publication date
KR20190116990A (ko) 2019-10-15
MX2019009500A (es) 2020-01-30
JP7271430B2 (ja) 2023-05-11
EP3581587A1 (en) 2019-12-18
KR102690437B1 (ko) 2024-07-30
AU2025203303A1 (en) 2025-05-29
EP3581587A4 (en) 2021-03-31
CN108409863A (zh) 2018-08-17
AU2017397778A1 (en) 2019-10-03
WO2018145533A1 (zh) 2018-08-16
RU2019128423A3 (enExample) 2021-03-19
EP3581587B1 (en) 2025-02-05
CA3054322A1 (en) 2018-08-16
CN108409863B (zh) 2023-09-26
JP2020507578A (ja) 2020-03-12
BR112019016300A2 (pt) 2020-06-16
RU2019128423A (ru) 2021-03-10

Similar Documents

Publication Publication Date Title
AU2017397778B2 (en) Anti-coagulation factor XI antibody
JP2022046656A (ja) 抗凝固因子ｘｉ抗体
JP2024054266A (ja) 組織因子経路インヒビター抗体およびその使用
US20230287141A1 (en) Anti-coagulation factor xi antibodies
CN114478781B (zh) 抗凝血因子xi抗体
JP2019510474A (ja) トロンビン抗体、その抗原結合フラグメント及び医薬用途
US11958911B2 (en) Anti-coagulation factor XI antibody
RU2800719C2 (ru) Антитела к фактору xi
HK40010556A (en) Anti-coagulation factor xi antibody
HK40075243A (en) Anticoagulant factor xi antibodies
HK40075244A (en) Anticoagulant factor xi antibodies
HK40075243B (zh) 抗凝血因子xi抗体
HK40075244B (zh) 抗凝血因子xi抗体
HK40057273A (en) Anti-factor xi antibodies
HK40057273B (zh) 抗凝血因子xi抗体
EA043303B1 (ru) Антитела к фактору свертывания xi

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)